Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant cholera toxin B subunit in active Crohn's disease
2005-002048-25Phase 2Terminated
- Sponsor
- SBL Vaccin AB
- Start
- Jun 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rCTB-401 in Crohn's disease, sponsored by SBL Vaccin AB. Primary endpoint: Clinical response by CDAI. Started Jun 2005; status: terminated.
02
Drugs
rCTB-401
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2005-002048-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002048-25.